| CELGENE CORP (NASDAQ:CELG) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $54.55 | 52 Week High | $58.34 | ||
| Open | $54.67 | 52 Week Low | $36.90 | ||
| Day High | $55.12 | P/E | 66.16 | ||
| Day Low | $54.28 | EPS | $0.83 | ||
| Volume | 3,146,572 | ||||
| More CELG Info: Chart SEC Filings Profile Historical Options | |||||
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States. Its lead products include THALOMID for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum, an inflammatory complication of ...more
Dr. Sol Barer - Chairman, CEO
Robert Hugin - President, COO, Secertary
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| F | 5 | BIIB | 5 |
| FITB | 4 | HOT | 4 |
| AMGN | 4 | COST | 4 |
| CL | 4 | LLL | 3 |
| MMM | 3 | EK | 3 |
| TGT | 3 | MO | 3 |
No comments are currently available.
on May 1, 2009
at 03:57 PM CLEGENE WONDER HOW THE ANALYSTS ARE RATING CREDIT SUISSE?
Article: Credit Suisse Downgrades Celgene (CELG) to Neutral
on May 1, 2009
at 12:28 PM Celgene Celgene has a great board and senior management. The bear sentiment has made those ready to reenter the market a great opportunity. Now is the time to buy into the Celgene stock and hold on to it. Only a true cynic would have trouble recognizing this great stock.
Article: Credit Suisse Downgrades Celgene (CELG) to Neutral
on May 1, 2009
at 10:11 AM celgene downgrade this is a wonderful buying opportunity UBS target is $64 company is buying back$500m shares fabulous day to get in and buy and buy AMERICAN ALWAYS
Article: Credit Suisse Downgrades Celgene (CELG) to Neutral
on May 1, 2009
at 09:06 AM celgeme celgrne is a buy is oversold a fantastic product line,a company that is actually ,positively helping patients all over the world live better lives through use of its products..no debt and a growing line of new solutions.a company announced $500m buyback is enoughh for me to say BUY CELGENE
Article: Credit Suisse Downgrades Celgene (CELG) to Neutral